KRYS KRYSTAL BIOTECH INC revenue, earnings and financials
For the quarter ended June 30, 2026, KRYSTAL BIOTECH INC reported revenue of $119M (up 24.1% from a year earlier), net income of $54.8M and diluted EPS of $1.79; over the last four quarters revenue was $440M and net income $241M; for the fiscal year ended December 2025 revenue was $389M, up 33.9% on the year before.
KRYS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $389M, gross profit n/a, operating income $161M, net income $205M (margin 52.6%), EPS $6.84
- Fiscal year ended Dec 2024: revenue $291M, gross profit n/a, operating income $65.7M, net income $89.2M (margin 30.7%), EPS $3.00
- Fiscal year ended Dec 2023: revenue $50.7M, gross profit n/a, operating income −$110M, net income $10.9M (margin 21.6%), EPS $0.39
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$145M, net income −$140M (margin n/a), EPS −$5.49
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$68.3M, net income −$69.6M (margin n/a), EPS −$3.13
KRYS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $119M (up 24.1% year over year), net income $54.8M, EPS $1.79
- Quarter ended Mar 31, 2026: revenue $116M (up 31.9% year over year), net income $55.9M, EPS $1.83
- Quarter ended Dec 31, 2025 (from the annual report): revenue $107M (up 17.5% year over year), net income $51.4M, EPS $1.69
- Quarter ended Sep 30, 2025: revenue $97.8M (up 16.6% year over year), net income $79.4M, EPS $2.66
- Quarter ended Jun 30, 2025: revenue $96.0M (up 36.6% year over year), net income $38.3M, EPS $1.29
- Quarter ended Mar 31, 2025: revenue $88.2M (up 94.9% year over year), net income $35.7M, EPS $1.20
- Quarter ended Dec 31, 2024 (from the annual report): revenue $91.1M (up 116.3% year over year), net income $45.5M, EPS $1.53
- Quarter ended Sep 30, 2024: revenue $83.8M (up 879.9% year over year), net income $27.2M, EPS $0.91
- Quarter ended Jun 30, 2024: revenue $70.3M, net income $15.6M, EPS $0.53
- Quarter ended Mar 31, 2024: revenue $45.3M, net income $932K, EPS $0.03
- Quarter ended Dec 31, 2023 (from the annual report): revenue $42.1M, net income $8.69M, EPS $0.61
- Quarter ended Sep 30, 2023: revenue $8.56M, net income $80.7M, EPS $2.79
- Quarter ended Jun 30, 2023: revenue $0, net income −$33.2M, EPS −$1.25
- Quarter ended Mar 31, 2023: revenue $0, net income −$45.3M, EPS −$1.76
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$32.1M, EPS −$1.23
- Quarter ended Sep 30, 2022: revenue $0, net income −$29.9M, EPS −$1.17
- Quarter ended Jun 30, 2022: revenue n/a, net income −$28.1M, EPS −$1.10
- Quarter ended Mar 31, 2022: revenue n/a, net income −$50.0M, EPS −$1.99
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$21.8M, EPS −$0.95
- Quarter ended Sep 30, 2021: revenue n/a, net income −$15.6M, EPS −$0.70
KRYS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $201M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $123M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$88.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$101M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$47.9M, share buybacks n/a
KRYS balance sheet
- Jun 30, 2026: cash $428M, total assets $1.50B, total liabilities $142M, shareholders' equity $1.36B
- Mar 31, 2026: cash $501M, total assets $1.40B, total liabilities $120M, shareholders' equity $1.28B
- Dec 31, 2025: cash $496M, total assets $1.33B, total liabilities $114M, shareholders' equity $1.22B
- Sep 30, 2025: cash $393M, total assets $1.24B, total liabilities $102M, shareholders' equity $1.14B
- Jun 30, 2025: cash $354M, total assets $1.14B, total liabilities $97.7M, shareholders' equity $1.04B
- Mar 31, 2025: cash $309M, total assets $1.07B, total liabilities $89.7M, shareholders' equity $985M
- Dec 31, 2024: cash $345M, total assets $1.06B, total liabilities $109M, shareholders' equity $946M
- Sep 30, 2024: cash $374M, total assets $982M, total liabilities $96.5M, shareholders' equity $886M
What is KRYS's revenue?
KRYSTAL BIOTECH INC reported $440M of revenue over its last four quarters, through June 30, 2026.
Is KRYS profitable?
Yes. KRYSTAL BIOTECH INC earned $241M over the last four quarters.
What is KRYS's EPS?
Diluted earnings per share over the last four quarters were $7.97; $1.79 in the latest quarter.